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L IVER TRANSPLANT patients require chronic admin-istration of immunosuppressive agents to prevent the 
rejection of transplanted organs. Such therapy usually 
includes low-dose steroids (prednisone) in combination with 
cyclosporine. 1 The exact dose of prednisone used is e~pir~­
cally determined and must be balanced between that which IS 
sufficient to maintain graft survival and that which causes 
minimal side effects. Since the availability and duration of 
unbound steroid at the receptor site is a determining factor 
for the time course of its pharmacologic action, a thorough 
understanding of the pharmacokinetic parameters, such as 
the rate and extent of absorption, protein binding, tissue 
distribution, biotransformation, and excretion, is very impor-
tant.2 Very little information is available on the pharmacoki-
netics of prednisone or prednisolone in liver transplant 
patients. The objective of the present study is to characte~ize 
the pharmacokinetics of prednisolone in clinically sta ble hver 
transplant patients. 
PATIENTS AND METHODS 
Ten liver transplant patients (eight females and 2 males) partici-
pated in this study. Informed consent was obtained from all subjects 
prior to the study. The patients fasted overnight and continued to 
fast for four hours after drug administration. Prednisolone was 
administered as an intravenous infusion of prednisolone phosphate at 
a mean dose of 19 mg. Multiple blood samples were obtained over 12 
hours after drug administration and plasma was analyzed by a 
high· pressure liquid chromatographic method.)·' Prednisolone bind-
ing to plasma protein was determined by equilibrium dialysis. Model 
independent pharmacokinetic parameters were calculated for pred-
nisolone accoring to standard methods. 5 
RESULTS 
All the patients who participated in this study were consid-
ered clinically stable based on serum biliru bin concentrations 
of 2 mg% or less. Table I shows the calculated pharmacoki-
netic parameters of prednisolone. The harmonic mean clear-
ance of total prednisolone was 0.087 (range, 0.053 to 0.113) 
L/hour /kg. The half-life of predinsolone r~nged from 3: I 
hours to 5.6 hours in this patient group, WIth a harmOniC 
mean half-life of 3.9. The harmonic mean clearance of 
unbound prednisolone was 0.27 (range. 0.18 to 0.66) L/ 
hour /kg. and the half-life was 2.5 hours (range. 2.0 to 4.0). 
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DISCUSSION 
The mean clearance of total prednisolone in liver transplant 
patients was approximately 40% lower than that observed in 
normal subjects. The half-life was also longer in transplant 
patients, compared to normal subjects. The mean clearance 
of unbound prednisolone in liver transplant patients was 
. lower than that reported in other subjects receiving predniso-
lone (0.58, 1.02, and 1.05 L/hour /kg) ... • 
For drugs that are primarily eliminated from the body by 
metabolism, a decrease in the unbound clearance indicates a 
reduced enzymatic activity for elimination of the drug. Our 
observations indicate that liver transplant patients do not 
metabolize prednisolone in a manner similar to that of other 
patient populations. Specific mechanisms responsible for the 
reduced intrinsic clearance of prednisolone are not clear at 
this point. It may be a reflection of the reduced steroid-
metabolizing activity in the liver. Additional exogeneous 
factors that may contribute to the decrease in the unbound 
clearance include the presence of cyclosporine, which has 
been documented to be an enzyme-inhibiting agent in animal 
models.' 
In summary, our studies indicate that a given dose of 
prednisolone would produce a higher concentration of ~his 
drug in liver transplant patients, compared to other patIent 
populations. 
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